Melssen, Marit M.
Pollack, Karlyn E.
Meneveau, Max O.
Smolkin, Mark E.
Pinczewski, Joel
Koeppel, Alexander F.
Turner, Stephen D.
Sol-Church, Katia
Hickman, Alexandra
Deacon, Donna H.
Petroni, Gina R.
Slingluff, Craig L. Jr http://orcid.org/0000-0002-6664-4373
Funding for this research was provided by:
GlaxoSmithKline
Beirne Carter Center Immunology Training Grant (T32AI007496)
National Institutes of Health (R01 CA057653)
Cancer Research Institute (Clinical Laboratory and Integration Project)
National Cancer Institute (P30 CA44579)
Rebecca Clary Harris Fellowship
Article History
Received: 29 March 2020
Accepted: 28 December 2020
First Online: 16 January 2021
Compliance with ethical standards
:
: C.L. Slingluff Jr. reports receiving commercial research grants from Merck, GlaxoSmithKline, 3 M, and Celldex; has ownership interest (including patents) in several of the peptides used in the 12MP vaccine with UVA Licensing and Ventures Group; and is a consultant/advisory board member for Immatics, Curevac, and Polynoma. No potential conflicts of interest were disclosed by the other authors.
: Clinical trials Mel48 and Mel55 were performed with IRB (#13498 and #15398, respectively) and FDA approval and are registered with Clinicaltrials.gov under NCT00705640 (Mel48) and NCT01425749 (Mel55). Patients provided written informed consent to participate.